Reviewing Akero Therapeutics (NASDAQ:AKRO) and BioMarin Pharmaceutical (NASDAQ:BMRN)

Akero Therapeutics (NASDAQ:AKRO) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

4.1% of Akero Therapeutics shares are owned by institutional investors. Comparatively, 96.3% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Akero Therapeutics and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akero Therapeutics 0 0 4 0 3.00
BioMarin Pharmaceutical 0 3 11 0 2.79

Akero Therapeutics presently has a consensus price target of $31.25, indicating a potential upside of 10.97%. BioMarin Pharmaceutical has a consensus price target of $115.60, indicating a potential upside of 52.59%. Given BioMarin Pharmaceutical’s higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Akero Therapeutics.

Profitability

This table compares Akero Therapeutics and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akero Therapeutics N/A N/A N/A
BioMarin Pharmaceutical -7.19% -3.12% -2.05%

Earnings and Valuation

This table compares Akero Therapeutics and BioMarin Pharmaceutical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akero Therapeutics N/A N/A N/A N/A N/A
BioMarin Pharmaceutical $1.49 billion 9.12 -$77.21 million ($0.33) -229.58

Akero Therapeutics has higher earnings, but lower revenue than BioMarin Pharmaceutical.

Summary

BioMarin Pharmaceutical beats Akero Therapeutics on 5 of the 9 factors compared between the two stocks.

About Akero Therapeutics

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.